Algeta, Avipep deal

Algeta and Avipep partnered to develop a targeted thorium conjugate (TTC) combining Algeta's thorium-227, an alpha-particle emitting radionuclide, with an undisclosed Avibody from Avipep for solid tumors. Both partners will contribute financially to the one-year deal, which may be extended. Avibodies combine recombinant antibody fragments with two, three or four target binding regions. The partners declined to disclose additional terms, and Avipep could not be reached for details. ...